There could soon be millions more British patients being prescribed cholesterol-lowering statins such as atorvastatin or pravastatin
to safeguard against heart attack and stroke, following the publication
of new guidelines in the United States of who would benefit from taking
statins; the first such guidance to be released in the US in a decade.
The updated guidelines are based upon the findings of a new study
conducted over four years by the American Heart Association and American
College of Cardiology, who decided to ‘think outside the box’ so to
speak, as to what constitutes putting someone at a risk of heart attack
and/ or stroke.
The researchers, unlike many of their
peers who conduct similar studies, shifted their interests away from
high cholesterol and instead utilised a formula to calculate risk and
looked at a person’s age, gender, race, together with certain health
factors like smoking.
“This guideline represents a departure from previous guidelines
because it doesn’t focus on specific target levels of LDL, or bad
cholesterol, although the definition of optimal LDL cholesterol has not
changed,” Dr Neil Stone, author of the report, said in a statement.
Dr Stone added: “The likely impact of the recommendations is that
more people who would benefit from statins are going to be on them.”
Dr Donald Lloyd-Jones, one of the experts who help to draft the new
guidelines, said: “We’ve been undertreating people who need statin
therapy. Statins lower cholesterol levels, but what they really target
is overall cardiovascular risk.”
More African-Americans – a demographic usually at a higher risk of
stroke – could be prescribed statins in accordance to the new
guidelines.
Under the guidance, there would now be approximately 44% of men and
22% of women who would be deemed suitable for taking statins – or
33 million Americans.
This is in stark contrast to previous US guidelines that meant only
15% of adults in America were recommended for statin treatment, whereby
patients had to have a target set to lower their cholesterol to. These
numerical targets have now seemingly been abandoned.
In creating the guidelines, the panel analysed four particular groups
who they believed to need statins more than most: patients currently
with heart disease, people with LDL levels of 190 or higher due to
genetic risk, adults aged between 40 and 75 with type 2 diabetes and
older adults with a 10-year risk of heart disease in excess of 7.5%.
Those in the panel also stressed the importance of a “diet pattern”
which includes fruit, vegetables and whole grains, with all adults
engaging in moderate to vigorous exercise three to four times per week.
Many of the patents on statins have expired, with significantly cheaper generic statins now available. Crestor
(rosuvastatin), a statin manufactured by AstraZeneca, still remains
under patent however and in 2012 alone the drug had impressive sales of
$8.3bn (£5.2bn).
Statins are actually the most commonly prescribed drugs in the UK,
used by almost a tenth of the population. As cholesterol is still the
primary factor in the process of prescribing statins, it is worth noting
that NHS guidelines state that LDL cholesterol should not be higher
than 3.0 and overall cholesterol no higher than 5.0.
No comments:
Post a Comment